<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03261284</url>
  </required_header>
  <id_info>
    <org_study_id>2017-P-032</org_study_id>
    <nct_id>NCT03261284</nct_id>
  </id_info>
  <brief_title>D-dimer to Guide Anticoagulation Therapy in Patients With Atrial Fibrillation</brief_title>
  <acronym>DATA-AF</acronym>
  <official_title>D-dimer to Determine Intensity of Anticoagulation to Reduce Clinical Outcomes in Patients With Atrial Fibrillation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wuhan Asia Heart Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Wuhan Asia Heart Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This was a prospective, three arms, randomized controlled study.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      D-dimer testing is performed in AF Patients receiving warfarin therapy (target INR:1.5-2.5)
      in Wuhan Asia Heart Hospital. Patients with elevated d-dimer levels (&gt;0.5ug/ml FEU) were
      SCREENED AND RANDOMIZED to three groups at a ratio of 1:1:1. First, NOAC group,the
      anticoagulant was switched to Dabigatran (110mg,bid) when elevated d-dimer level was detected
      during warfarin therapy.Second,Higher-INR group, INR was adjusted to higher level
      (INR:2.0-3.0) when elevated d-dimer level was detected during warfarin therapy. Third,
      control group, patients with elevated d-dimer levels have no change in warfarin therapy.
      Warfarin is monitored once a month by INR ,and dabigatran dose not need monitor. All patients
      were followed up for 24 months until the occurrence of endpoints, including bleeding events,
      thrombotic events and all-cause deaths.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">September 1, 2017</start_date>
  <completion_date type="Anticipated">December 30, 2019</completion_date>
  <primary_completion_date type="Anticipated">December 30, 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Thrombotic events</measure>
    <time_frame>24 months</time_frame>
    <description>Stroke, DVT, PE, Peripheral arterial embolism, ACS etc.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>hemorrhagic events</measure>
    <time_frame>24 months</time_frame>
    <description>cerebral hemorrhage,Gastrointestinal bleeding etc.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>all-cause deaths</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">600</enrollment>
  <condition>Atrial Fibrillation</condition>
  <condition>Thrombosis</condition>
  <condition>Hemorrhage</condition>
  <condition>Anticoagulant Adverse Reaction</condition>
  <arm_group>
    <arm_group_label>DOAC group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with elevated d-dimer levels was switched to DOAC (dabigatran 150mg, bid).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Higher-INR group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients' target INR was adjusted from 1.5-2.5 to 2.0-3.0 by adding warfarin dose.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Patients continue previous strategy without change.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dabigatran Etexilate 150 MG [Pradaxa]</intervention_name>
    <description>Dabigatran Etexilate 150mg,bid</description>
    <arm_group_label>DOAC group</arm_group_label>
    <other_name>Pradaxa</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Warfarin Pill</intervention_name>
    <description>Add warfarin dose according to INR values.</description>
    <arm_group_label>Higher-INR group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with non-valvular atrial fibrillation

          -  Receiving warfarin therapy

        Exclusion Criteria:

          -  Patients who had suffered from recent (within 3 months) myocardial infarction,
             ischemic stroke, deep vein thrombosis, cerebral hemorrhages, or other serious
             diseases.

          -  Those who had difficulty in compliance or were unavailable for follow-up.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Zhenlu ZHANG, MD,PhD</last_name>
    <role>Study Director</role>
    <affiliation>Wuhan Asia Heart Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Litao Zhang, MD</last_name>
    <phone>15623010240</phone>
    <email>zhangleetau@qq.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Zhenlu Zhang, MD,PhD</last_name>
    <phone>027-65796739</phone>
    <email>zhenluzhangwh@163.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Zhang litao</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <zip>430022</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Litao ZHANG, MD</last_name>
      <phone>15623010240</phone>
      <email>zhangleetau@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 22, 2017</study_first_submitted>
  <study_first_submitted_qc>August 23, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">August 24, 2017</study_first_posted>
  <last_update_submitted>August 23, 2017</last_update_submitted>
  <last_update_submitted_qc>August 23, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 24, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>D-dimer</keyword>
  <keyword>Nonvalvular atrial fibrillation</keyword>
  <keyword>Direct thrombin inhibitor</keyword>
  <keyword>INR</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
    <mesh_term>Hemorrhage</mesh_term>
    <mesh_term>Thrombosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Warfarin</mesh_term>
    <mesh_term>Dabigatran</mesh_term>
    <mesh_term>Fibrin fragment D</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

